Vaxart, Inc.
Moat Score — Vaxart, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Three U.S. platform patents and over 25 foreign tablet-formulation patents around the VAAST oral vaccine platform represent real, differentiated IP, and the underlying Ad5 vector has over 200 trials of validation history from other developers. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Room-temperature-stable tablets avoid cold-chain logistics costs that injectable vaccines require, a genuine structural cost advantage in distribution, though Vaxart's own manufacturing scale is small relative to major vaccine makers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved product and heavy reliance on government funding (BARDA) that has already been disrupted, Vaxart has no current pricing power, and legacy Inavir royalties are actively eroding from generic competition. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Oral vaccine tablets carry no network effect -- one person's vaccination does not make the product more valuable to another. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product in Vaxart's core pipeline, there is no installed base or switching cost to speak of; any future stickiness would depend on health-system procurement relationships not yet established. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The oral-tablet vaccine delivery niche is genuinely underserved by major vaccine makers who are built around injectable platforms, giving Vaxart some first-mover room, but its funding instability (BARDA stop-work orders) shows it lacks the scale to pursue this niche independent of government support. |